Pacira BioSciences (PCRX) Fundamental Analysis: Revenue, Earnings & Valuation

4.17 / 10

Netural

Fundamental analysis rates PCRX at 4.2/10, indicating fair health. Strengths include strong inventory turnover (1.08) and low cost‑of‑sales ratio (20.6%). Weaknesses are modest revenue growth (3.6% YoY), a low long‑term debt‑to‑working‑capital ratio, and negative PB‑ROE, leading to a guarded view.

Analysis Checks(6/10)

Revenue-MV

Value0.17

Score2/3

Weight25.23%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value3.63

Score1/3

Weight-1.56%

1M Return-0.38%

Inventory turnover ratio

Value1.08

Score3/3

Weight-3.91%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value21.09

Score2/3

Weight1.54%

1M Return0.36%

PB-ROE

Value-0.12

Score3/3

Weight50.11%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value1.06

Score1/3

Weight-2.67%

1M Return-0.65%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.61%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value3.63

Score1/3

Weight-1.22%

1M Return-0.30%

Cost of sales ratio (%)

Value20.61

Score3/3

Weight1.15%

1M Return0.26%

Asset-MV

Value-0.55

Score1/3

Weight35.94%

1M Return6.31%

Is PCRX fundamentally strong?

PCRX scores 4.17/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.96% ROE, 0.97% net margin, 130.09 P/E ratio, 1.32 P/B ratio, and 107.44% earnings growth, these metrics solidify its Netural investment rating.